The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis

dc.creatorTorresan, M
dc.creatorMachado, TFGS
dc.creatorSiqueira, LH
dc.creatorOzelo, MC
dc.creatorArruda, VR
dc.creatorAnnichino-Bizzacchi, JM
dc.date2000
dc.dateOCT
dc.date2014-12-02T16:30:04Z
dc.date2015-11-26T16:43:41Z
dc.date2014-12-02T16:30:04Z
dc.date2015-11-26T16:43:41Z
dc.date.accessioned2018-03-28T23:28:46Z
dc.date.available2018-03-28T23:28:46Z
dc.identifierBlood Coagulation & Fibrinolysis. Lippincott Williams & Wilkins, v. 11, n. 7, n. 679, n. 682, 2000.
dc.identifier0957-5235
dc.identifierWOS:000165162000014
dc.identifier10.1097/00001721-200010000-00014
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/73755
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/73755
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/73755
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1273668
dc.descriptionThrombosis is a major clinical feature of the antiphospholipid syndrome. Interactions between genetic and acquired factors could contribute to thrombosis development. In this study, we evaluated 40 patients with antiphospholipid syndrome and thrombosis, 31 primary and nine secondary to systemic lupus erythemathosus, to estimate the carrier rates of factor V Leiden, 20210A --> G prothrombin variant and 677C --> T in the MTHFR gene. Protein C, protein S and antithrombin were measured in 30 patients, with a median of 100.66 +/- 23.86, 93.57 +/- 36.44 and 98.8 +/- 5.67%, respectively. None of the patients were deficient on these natural anticoagulants. No significant variation was found between the patient group and the controls, regarding the prevalence of homozygotes for the mutated 677T allel (2.5 versus 5.4%), or heterozygotes for factor V Leiden (0 versus 0.7%). Despite the fact that these mutations are relatively common in Brazilian thrombophilc patients, its low prevalence in this cohort of patients suggest that these genetic alterations are not risk factors for thrombosis in antiphospholipid syndrome. The prevalence of the mutated allele 20210A of the prothrombin gene was higher in patients when compared with controls (5 versus 0.7%; P = 0.01), suggesting that prothrombin variant could increase the risk of thrombosis in patients with antiphospholipid syndrome. Blood Coagul Fibrinolysis 11:679-682 (C) 2000 Lippincott Williams & Wilkins.
dc.description11
dc.description7
dc.description679
dc.description682
dc.languageen
dc.publisherLippincott Williams & Wilkins
dc.publisherPhiladelphia
dc.publisherEUA
dc.relationBlood Coagulation & Fibrinolysis
dc.relationBlood Coagul. Fibrinolysis
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectantiphospholipid syndrome
dc.subjectthrombosis
dc.subjectfactor V Leiden
dc.subjectprothrombin variant
dc.subjectMTHFR-T
dc.subjectFactor-v-leiden
dc.subjectSystemic Lupus-erythematosus
dc.subjectVenous Thrombosis
dc.subjectArterial-disease
dc.subjectProthrombin Gene
dc.subjectMutation
dc.subjectAntibodies
dc.subjectCommon
dc.subjectPrevalence
dc.subjectCriteria
dc.titleThe impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución